Poging GOUD - Vrij
Henry Kissinger, US diplomat and Nobel winner, dies at 100
Mint Mumbai
|December 01, 2023
Kissinger had a hand in many epoch-changing global events of the 1970s while he was US secretary of state
-
Henry Kissinger, a diplomatic powerhouse whose roles as a national security adviser and secretary of state under two presidents left an indelible mark on US foreign policy and earned him a controversial Nobel Peace Prize, died on Wednesday at age 100.
Kissinger died at his home in Connecticut, according to a statement from his geopolitical consulting firm, Kissinger Associates Inc. No mention was made of the circumstances.
It said he would be interred at a private family service, to be followed at a later date by a public memorial service in New York City.
Kissinger had been active late in life, attending meetings in the White House, publishing a book on leadership styles, and testifying before a Senate committee about the nuclear threat posed by North Korea. In July 2023 he made a surprise visit to Beijing to meet Chinese President Xi Jinping.
During the 1970s in the midst of the Cold War, he had a hand in many of the epoch-changing global events of the decade while serving as national security adviser and secretary of state under Republican President Richard Nixon.
The German-born Jewish refugee's efforts led to the US diplomatic opening with China, landmark US-Soviet arms control talks, expanded ties between Israel and its Arab neighbours, and the Paris Peace Accords with North Vietnam.
Dit verhaal komt uit de December 01, 2023-editie van Mint Mumbai.
Abonneer u op Magzter GOLD voor toegang tot duizenden zorgvuldig samengestelde premiumverhalen en meer dan 9000 tijdschriften en kranten.
Bent u al abonnee? Aanmelden
MEER VERHALEN VAN Mint Mumbai
Mint Mumbai
Gen Alpha will make new rules for their workplace
Gen Alpha will expect hybrid workplaces, Al tools and 4-day weeks— offices unrecognizable to their parents’
3 mins
December 01, 2025
Mint Mumbai
EC extends electoral roll revision by a week to II Dec; final list on 14 Feb
The Election Commission on Sunday extended by one week the entire schedule of the ongoing special intensive revision (SIR) of electoral rolls in nine states and three Union territories amid allegations by opposition parties that the “tight timelines” were creating problems for people and ground-level poll officials.
2 mins
December 01, 2025
Mint Mumbai
THE PROBLEM IS NOT JUST ABOUT DYNASTIC POLITICS
These days Tejashvi Yadav is the target of intense trolling. Before him the Huda family in Haryana and Thackerays in Maharashtra got the same treatment. So, is the battle of victory and defeat in electoral politics a tussle between dynasts vs the rest? Absolutely not.
3 mins
December 01, 2025
Mint Mumbai
Green hydrogen: Fast fashion could help bump up demand
A boom in its use for clean synthetic inputs might make a difference
3 mins
December 01, 2025
Mint Mumbai
Let's be a bit more selective in using the word 'reforms'
Everybody should take a beat and think before uttering the word ‘reforms’ the next time. Glib usage, frequently in the wrong context, threatens to rob the word of its import.
3 mins
December 01, 2025
Mint Mumbai
As mid-cap alpha shrinks, should you consider passive strategies?
Advisers urge a balanced mix—add passives slowly and back strong, active managers, as mid-caps are still pricey
4 mins
December 01, 2025
Mint Mumbai
With $2.2 bn fund, ChrysCap has appetite for riskier bets
MD Saurabh Chatterjee details shift in global LP base, renewed focus on manufacturing
3 mins
December 01, 2025
Mint Mumbai
GDP growth of 8% plus: How to sustain this pace
Last quarter's economic expansion has cheered India but the challenge is to sustain a brisk rate for years to come. For private investment to chip in, revive infrastructure partnerships
2 mins
December 01, 2025
Mint Mumbai
INSIDE INDIA'S ATTEMPT TO TAME DEEPFAKES
Detection tools today are not universal or consistent across languages
5 mins
December 01, 2025
Mint Mumbai
APIs to innovation: Bulk drug makers ramp up CDMO bets
Once focused on low-margin active pharmaceutical ingredients (APIs), India’s bulk drug manufacturers are raising their ambitions, with several now investing heavily in research and development to win contract development and manufacturing work from global drugmakers.
2 mins
December 01, 2025
Translate
Change font size

